RxDoctor Payments Data

Zhengyu Hu, MD

Pain Medicine · Overland Park, KSNPI 1366498867

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.6% of the total across 168 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations.

$3,548in general payments, 2019–2025

Across 168 payments — averaging $21.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$788
  • Scilex Pharmaceuticals Inc.$468
  • Biodelivery Sciences International, Inc.$401
  • Amgen$302
  • Pfizer$280
  • Abbott$238
  • plus $1K from 23 others

What the payments were for

  • Travel & lodging$1554%
  • Food & beverage$3,39296%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,548 in reported general payments places this provider in the 55th percentile of 64 pain medicine providers in Kansas.

See all pain medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$7,448
Medicare patients
21
Services billed
104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl30$27,407
NucyntaTapentadol Hcl11$9,583
Buprenorphine13$1,117
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen53$1,110
Pregabalin27$690
Gabapentin59$671
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen14$605
Tramadol Hcl67$597
Tizanidine Hcl45$404
Duloxetine Hcl24$349
Morphine Sulfate ErMorphine Sulfate22$298
Oxycodone Hcl26$263
Acetaminophen-CodeineAcetaminophen With Codeine14$255
Methocarbamol12$138
Baclofen11$112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Nucynta$788$36,99141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 64 pain medicine providers in Kansas.

Other pain medicine in Overland Park

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →